https://clinicaltrials.gov/study/NCT06255990?term=skin%20substitute&rank=6
A 42-patient CT will investigate a novel dermal substitute, NovoSorb BTM, for the treatment of full-thickness skin defects versus SoC with primary outcome of skin elasticity at 1 year post-transplantation vs normal skin. Recruitment is ongoing with estimated study completion in June 2027. clinicaltrials.gov
The Clinicians Speak, page-890
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.61 |
Change
0.160(6.53%) |
Mkt cap ! $1.802B | |||
| Open | High | Low | Value | Volume |
| $2.50 | $2.61 | $2.48 | $4.801M | 1.866M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2558 | $2.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.61 | 64745 | 5 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| PNV (ASX) Chart |